Cronos Australia has rolled out upgraded elements of its CanView platform with pharmacies now able to receive prescriptions and TGA approvals directly from doctors who are prescribing through the system.

All 3,000 pharmacy accounts have successfully transitioned to the new version in a “seamless” manner with “no interruption to regular operations”, the company said.

It also allows patients to order repeat prescriptions, while pharmacies will be provided with auto-matching functionality for products and dosage forms based on TGA approvals.

Cronos said it has also completed stage three of CanView 2.0 – that will focus on doctors and patients – with elements to be rolled out in early October.

Among the enhancements for doctors will be the ability to generate electronic prescriptions within the CanView platform. They will also be able to store TGA approval documents in one location and send those approvals directly to pharmacies along with electronic prescriptions.

Patients, meanwhile, will be able to receive prescriptions from CanView prescribers and order repeats from pharmacies through the mobile app.

Cronos Australia chief executive Rodney Cocks said: “We are very pleased to be delivering such a wide range of important new features to our large and growing number of CanView users. The network effect on the platform is clear which will drive further patient, prescriber and pharmacist onboarding.

“We are confident that the improved functionality of the CanView 2.0 platform will not only provide a superior user experience but help Cronos Australia to maintain its current market-leading position.”

Cocks stressed the developments are the outcome from an “aligned focused board and executive with proven execution capabilities”.

The comments come a day after CDA co-founder and major Cronos shareholder Dr Matua Jansen called for a “complete separation of the board and executive management” and signalled his intention to seek the removal of Cocks and director Guy Headley from the board.

Cronos shares climbed 7% to $0.60 in today’s trading.

Steve has reported for a number of consumer and B2B titles over a journalism career spanning more than three decades. He is a regulator contributor to health journal, The Medical Republic, writing on...

Leave a comment